Resveratrol in acute ischemic stroke

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 76

Inclusion Criteria

Willingness to cooperate and complete the informed consent form by the patient or legal guardian, patients aged 18-85 years, body mass index = 35 kg/m2, starting the intervention within 24 hours after being admitted to the ICU and not spending More than 24 hours from the time of disease diagnosis until the time of entering the study, the severity of stroke based on the NIHSS standard is higher than 4, the patient's GCS at the time of visit is higher than 3, feeding by enteral feeding method, receiving at least 80 percent of the prescribed formula during the first 48 hours, none Absolute contraindications for enteral feeding (permanent ileus, ischemia of the digestive tract, bilious or continuous vomiting and mechanical obstruction), the possibility of hospitalization in the intensive care unit (ICU) for 30 days, not suffering from hepatic encephalopathy and liver cirrhosis, not suffering from metastatic cancer, not having infection and sepsis, not having AIDS (HIV), not having hepatitis, not receiving supplements or formulas that strengthen the immune system, including arginine, glutamine, colostrum, vitamins C and E, selenium, zinc or Omega-3 fatty acids or resveratrol supplement during the last 30 days before the start of the intervention, not suffering from allergies or intolerance to the enteral formula used in the present study and resveratrol supplement, non-participation in other interventional studies. No company in the past 30 days in other clinical trial studies at the same time as the present study

Exclusion Criteria

Pregnancy, lactation, intracranial hemorrhage, history of previous stroke, consumption of any natural food containing resveratrol within 48 hours before the onset of stroke, patients who received rtPA, more than 24 hours from onset of symptoms, seizure at onset Stroke, intracranial hemorrhage, symptoms suggestive of subarachnoid hemorrhage, rapid recovery or partial symptoms, stroke severity based on NIHSS criteria less than 4, patient suffering from dementia before stroke

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IL-1ß gene expression. Timepoint: At the beginning of the study and 30th day. Method of measurement: Real-time PCR.;Stroke severity score NIHSS: National Institutes of Health Stroke Scale. Timepoint: At the beginning of the study and 30th day. Method of measurement: Physical examination.

Secondary Outcome Measures